Insulin, insulin-like growth factor-I, and risk of breast cancer in postmenopausal women
- PMID: 19116382
- PMCID: PMC2639294
- DOI: 10.1093/jnci/djn415
Insulin, insulin-like growth factor-I, and risk of breast cancer in postmenopausal women
Abstract
Background: The positive association between obesity and postmenopausal breast cancer has been attributed, in part, to the fact that estrogen, a risk factor for breast cancer, is synthesized in adipose tissue. Obesity is also associated with high levels of insulin, a known mitogen. However, no prospective studies have directly assessed associations between circulating levels of insulin and/or insulin-like growth factor (IGF)-I, a related hormone, and the risk of breast cancer independent of estrogen level.
Methods: We conducted a case-cohort study of incident breast cancer among nondiabetic women who were enrolled in the Women's Health Initiative Observational Study (WHI-OS), a prospective cohort of 93,676 postmenopausal women. Fasting serum samples obtained at study entry from 835 incident breast cancer case subjects and from a subcohort of 816 randomly chosen WHI-OS subjects were tested for levels of insulin, glucose, total IGF-I, free IGF-I, insulin-like growth factor binding protein-3, and estradiol. Multivariable Cox proportional hazards models were used to estimate associations between levels of the serologic factors and baseline characteristics (including body mass index [BMI]) and the risk of breast cancer. All statistical tests were two-sided. Results Insulin levels were positively associated with the risk of breast cancer (hazard ratio [HR] for highest vs lowest quartile of insulin level = 1.46, 95% confidence interval [CI] = 1.00 to 2.13, P(trend) = .02); however, the association with insulin level varied by hormone therapy (HT) use (P(interaction) = .01). In a model that controlled for multiple breast cancer risk factors including estradiol, insulin level was associated with breast cancer only among nonusers of HT (HR for highest vs lowest quartile of insulin level = 2.40, 95% CI = 1.30 to 4.41, P(trend) < .001). Obesity (BMI >or=30 kg/m(2)) was also associated with the risk of breast cancer among nonusers of HT (HR for BMI >or=30 kg/m(2) vs 18.5 to <25 kg/m(2) = 2.12, 95% CI = 1.26 to 3.58, P(trend) = .003); however, this association was attenuated by adjustment for insulin (P(trend) = .40).
Conclusion: These data suggest that hyperinsulinemia is an independent risk factor for breast cancer and may have a substantial role in explaining the obesity-breast cancer relationship.
Comment in
-
Re: Insulin, insulin-like growth factor-I, and risk of breast cancer in postmenopausal women.J Natl Cancer Inst. 2009 Jul 15;101(14):1030-1; author reply 1031-2. doi: 10.1093/jnci/djp158. Epub 2009 Jun 22. J Natl Cancer Inst. 2009. PMID: 19546433 No abstract available.
Similar articles
-
Circulating Adipokines and Inflammatory Markers and Postmenopausal Breast Cancer Risk.J Natl Cancer Inst. 2015 Jul 16;107(9):djv169. doi: 10.1093/jnci/djv169. Print 2015 Sep. J Natl Cancer Inst. 2015. PMID: 26185195 Free PMC article.
-
A prospective evaluation of insulin and insulin-like growth factor-I as risk factors for endometrial cancer.Cancer Epidemiol Biomarkers Prev. 2008 Apr;17(4):921-9. doi: 10.1158/1055-9965.EPI-07-2686. Cancer Epidemiol Biomarkers Prev. 2008. PMID: 18398032 Free PMC article.
-
Insulin, insulin-like growth factor-I, endogenous estradiol, and risk of colorectal cancer in postmenopausal women.Cancer Res. 2008 Jan 1;68(1):329-37. doi: 10.1158/0008-5472.CAN-07-2946. Cancer Res. 2008. PMID: 18172327 Free PMC article.
-
Breast Cancer and Menopausal Hormone Therapy by Race/Ethnicity and Body Mass Index.J Natl Cancer Inst. 2015 Nov 5;108(2):djv327. doi: 10.1093/jnci/djv327. Print 2016 Feb. J Natl Cancer Inst. 2015. PMID: 26546117 Free PMC article. Review.
-
Systematic review of insulin-like growth factor 1 gene expression in women with breast cancer.Rev Assoc Med Bras (1992). 2021 Sep;67(9):1372-1376. doi: 10.1590/1806-9282.20210220. Rev Assoc Med Bras (1992). 2021. PMID: 34816937 No abstract available.
Cited by
-
Second malignancies following conventional or combined ²⁵²Cf neutron brachytherapy with external beam radiotherapy for breast cancer.J Radiat Res. 2013 Sep;54(5):872-9. doi: 10.1093/jrr/rrt009. Epub 2013 Feb 7. J Radiat Res. 2013. PMID: 23397075 Free PMC article.
-
Diet-induced metabolic change induces estrogen-independent allometric mammary growth.Proc Natl Acad Sci U S A. 2012 Oct 2;109(40):16294-9. doi: 10.1073/pnas.1210527109. Epub 2012 Sep 17. Proc Natl Acad Sci U S A. 2012. PMID: 22988119 Free PMC article.
-
Aromatase expression and regulation in breast and endometrial cancer.J Mol Endocrinol. 2016 Jul;57(1):R19-33. doi: 10.1530/JME-15-0310. Epub 2016 Apr 11. J Mol Endocrinol. 2016. PMID: 27067638 Free PMC article. Review.
-
Associations of Insulin and IGFBP-3 with Lung Cancer Susceptibility in Current Smokers.J Natl Cancer Inst. 2016 Apr 12;108(7):djw012. doi: 10.1093/jnci/djw012. Print 2016 Jul. J Natl Cancer Inst. 2016. PMID: 27071409 Free PMC article.
-
Body fat and breast cancer risk in postmenopausal women: a longitudinal study.J Cancer Epidemiol. 2013;2013:754815. doi: 10.1155/2013/754815. Epub 2013 Apr 7. J Cancer Epidemiol. 2013. PMID: 23690776 Free PMC article.
References
-
- American Cancer Society. Cancer Facts and Figures 2008.
-
- van den Brandt PA, Spiegelman D, Yaun SS, et al. Pooled analysis of prospective cohort studies on height, weight, and breast cancer risk. Am J Epidemiol. 2000;152(6):514–527. - PubMed
-
- Vainio H, Kaaks R, Bianchini F. Weight control and physical activity in cancer prevention: international evaluation of the evidence. Eur J Cancer Prev. 2002;11(suppl 2):S94–S100. - PubMed
-
- Ahn J, Schatzkin A, Lacey JV, Jr, et al. Adiposity, adult weight change, and postmenopausal breast cancer risk. Arch Intern Med. 2007;167(19):2091–2102. - PubMed
-
- Lahmann PH, Hoffmann K, Allen N, et al. Body size and breast cancer risk: findings from the European Prospective Investigation into Cancer and Nutrition (EPIC) Int J Cancer. 2004;111(5):762–771. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- N01WH42124/WH/WHI NIH HHS/United States
- N01WH32102/WH/WHI NIH HHS/United States
- N01WH22110/WH/WHI NIH HHS/United States
- N01WH42112/WH/WHI NIH HHS/United States
- N01WH42119/WH/WHI NIH HHS/United States
- N01WH32112/WH/WHI NIH HHS/United States
- N01WH32101/WH/WHI NIH HHS/United States
- N01WH32119/WH/WHI NIH HHS/United States
- N01WH32105/WH/WHI NIH HHS/United States
- N01WH42132/WH/WHI NIH HHS/United States
- N01WH42121/WH/WHI NIH HHS/United States
- N01WH42113/WH/WHI NIH HHS/United States
- N01WH42125/WH/WHI NIH HHS/United States
- N01WH32106/WH/WHI NIH HHS/United States
- N01WH42129/WH/WHI NIH HHS/United States
- N01WH42108/WH/WHI NIH HHS/United States
- N01WH42118/WH/WHI NIH HHS/United States
- N01WH32113/WH/WHI NIH HHS/United States
- N01WH42120/WH/WHI NIH HHS/United States
- N01WH32118/WH/WHI NIH HHS/United States
- N01WH42131/WH/WHI NIH HHS/United States
- N01WH42109/WH/WHI NIH HHS/United States
- R01-CA93881-01/CA/NCI NIH HHS/United States
- N01WH42114/WH/WHI NIH HHS/United States
- N01WH32122/WH/WHI NIH HHS/United States
- N01WH42107/WH/WHI NIH HHS/United States
- N01WH32111/WH/WHI NIH HHS/United States
- N01WH42130/WH/WHI NIH HHS/United States
- N01WH42117/WH/WHI NIH HHS/United States
- N01WH42115/WH/WHI NIH HHS/United States
- N01WH42111/WH/WHI NIH HHS/United States
- N01WH32109/WH/WHI NIH HHS/United States
- N01WH32108/WH/WHI NIH HHS/United States
- N01WH42122/WH/WHI NIH HHS/United States
- N01WH32100/WH/WHI NIH HHS/United States
- N01WH42123/WH/WHI NIH HHS/United States
- N01WH32115/WH/WHI NIH HHS/United States
- N01WH44221/WH/WHI NIH HHS/United States
- N01WH24152/WH/WHI NIH HHS/United States
- N01WH42110/WH/WHI NIH HHS/United States
- N01WH42126/WH/WHI NIH HHS/United States
- N01WH42116/WH/WHI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical